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Abstract
Background—The p53 and the PIK3CA/AKT/mTOR pathways are frequently altered in
sarcoma with complex genomics such as leiomyosarcoma (LMS) or undifferentiated pleomorphic
sarcoma (UPS). The scale of genetic abnormalities in these pathways remains unknown in
angiosarcoma.
Methods—We investigated the status of critical genes involved in the p53 and the PIK3CA/
AKT/mTOR pathways in a series of 62 AS.
Results—The mutation and deletion rates of TP53 were 4% and 0, respectively. p53
overexpression was detected by immunohistochemistry in 49% of cases and was associated with
inferior disease-free survival. Although p14 inactivation or HDM2 overexpression are frequent in
LMS and UPS and could substitute for TP53 mutation or deletion, such alterations were rare in
angiosarcomas. pS6K and/or p-4eBP1 overexpression was observed in 42% of cases suggesting
frequent activation of the PIK3CA/AKT/mTOR pathway in angiosarcomas. Activation was not
related to intragenic deletion of PTEN, an aberration that is frequent in LMS and UPS, but absent
in angiosarcomas.
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Conclusion—Angiosarcomas constitute a distinct subgroup among sarcomas with complex
genomics. Although TP53 mutation and PTEN deletion are frequent in LMS and UPS, these
aberrations are rarely involved in the pathogenesis of AS.
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INTRODUCTION
Angiosarcomas (AS) represent a rare (<2%) subgroup of soft tissue sarcomas (STS)
characterized by an aggressive clinical behavior and occurring not only in different
anatomical locations, but also in distinct clinical settings, such as de novo (primary AS), or
after radiation therapy or chronic lymphedema (secondary AS) 1. Radical surgery and
adjuvant radiotherapy when indicated represent the cornerstone of treatment for patients
with localized disease. However, despite an adequate loco-regional treatment, half or more
of patients will develop metastatic relapse and will die of disease 2. The genetic aberrations
involved in AS genesis are still poorly understood. Until recently, data were limited to case
reports or small case series showing a complex pattern of numerical and structural genetic
aberrations 3-11. We and others have recently identified MYC amplification as a recurrent
genetic aberration in secondary AS 12, 13, but no specific recurrent event has been reported
in primary AS to date.
Alterations of TP53 or PTEN are among the most frequent genetic events in human cancer
and the role of their combined inactivation in tumorigenesis has been well examined in
several contexts, including lymphoma, prostate cancer, glioblastoma, and
medulloblastoma 14-20. Interestingly, the p53 and the PIK3CA/AKT/mTOR pathways are
frequently altered in sarcoma with complex karyotypes. Mutations and/or deletions of the
TP53 gene have been recently shown to occur in approximately 80% of leiomyosarcomas
(LMS), 70% of undifferentiated pleomorphic sarcoma (UPS), and 60% of pleomorphic
liposarcomas 21-23. Large deletions on chromosome 10 including the tumor suppressor gene
PTEN have also been observed in approximately 40-50% of LMS and 20-25% of UPS 24, 25.
Moreover, in vitro and in vivo studies 25, 26 suggest the crucial role of the PIK3CA/AKT/
mTORpathway in LMS genesis. Due to its rarity, studies regarding the incidence of p53 and
PIK3CA/AKT/mTOR pathway aberrations in AS have used heterogeneous methods and are
based on single case reports or small case series 27-35. Therefore, we investigated the status
of key genes involved in these pathways in a series of primary and secondary AS by
sequencing, array CGH and immunohistochemistry.
PATIENTS AND METHODS
Patient and samples
Sixty-two AS (30 primary and 32 secondary) were included in this study on the basis of
availability of tumor material for genetic studies. The clinico-pathologic characteristics are
listed in Table 1. Diagnoses were established according to the World Health Organization
Classification of Tumors 1. This study was approved by the institutional review board (IRB-
protocol 02-060).
Array Comparative Genomic Hybridization (CGH)
Genomic DNA was isolated from frozen tumor tissue by phenol/chloroform extraction and
quality was confirmed by spectrophotometry and electrophoresis. Array CGH analysis was
performed as described previously (Thomas et al., 2011). Briefly, tumor and reference DNA
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samples were labeled with Cyanine-3-dUTP and Cyanine-5-dUTP, respectively, by random
priming (Agilent Enzymatic Labeling Kit, Agilent Technologies, Santa Clara, CA). The
reference sample comprised a pool of DNA from multiple clinically healthy donors
(Promega, Madison, WI) of the same gender as the AS patient. The labeled probes were
combined and hybridized to a ~180,000-feature, genome-wide oligonucleotide CGH array
(design 052252, Agilent Technologies). Arrays were scanned at 3μm resolution using an
Agilent G2565CA scanner. Image data were processed with Feature Extraction version
10.10 and Genomic Workbench version 6.5 (Agilent Technologies). Data were filtered to
exclude probes exhibiting non-uniform hybridization or signal saturation and were
normalized using the centralization algorithm with a threshold of six. The ADM2 algorithm
was used to define DNA copy number aberrations using a ‘three probes minimum’ filter and
a threshold of six with a fuzzy zero correction, with genomic gain and loss defined as log2
test:reference DNA signal intensity >0.2 and <−0.2, respectively. A genomic copy number
amplification was defined as a region within which the log2 ratio of tumor DNA to reference
DNA exceeded 2.0.
Real-Time Quantitative Reverse Transcription-PCR
One μg of total RNA was reverse-transcribed using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA) at 25°C for 10 min, 37°C for 120
min, 85°C for five min and hold at 4°C. Twenty ng/μl of resultant cDNA was used in a
quantitative-PCR using an 7500 Real-Time PCR System (Applied Biosystems, Carlsbad,
CA) and pre-designed TaqMan ABI Gene expression Assays (Hs_00234753_m1 for HDM2;
Hs_99999189_m1 for P14/CDKN2A). Amplification was carried out at 95°C for 10 min,
and 40 cycles (95°C for 15 sec, 60°C for one min). To calculate the efficiency of the PCR
and to assess the sensitivity of each assay, we also performed a five point standard curve
(80, 26.67, 8.88, 2.96, and 0.98 ng/ul). Triplicates CT values were averaged and amounts of
target were interpolated from the standard curves and normalized to GAPDH (reference
gene).
Mutation Screening
The mutational status of TP53 (exon 2 to exon 11), PIK3CA (exons 3, 10, 20), BRAF (exon
15) and NRAS (exons 2 and 3) was assessed by direct sequencing of genomic DNA.
Protocols and primers are available on request. Sequence analysis was performed with
Applied Biosystems Sequence ScannerTM v1.0.
Enhanced Mismatch Mutation Detection Analysis (EMMA) and Copy Number Analysis by
Quantitative Multiplex PCR (QMP)
A screening of genomic variants of PTEN was performed by using Enhanced Mismatch
Mutation Detection Analysis (EMMA), an electrophoretic heteroduplex analysis based on
the use of a matrix increasing the electrophoretic mobility between homoduplex and
heteroduplex 36. Primers were designed to include flanking intronic sequences (at least 50
base-pairs from splices sites) and to avoid known polymorphism and prevent mis-priming
(primer sequences are available upon request). PTEN coding sequences were divided into
nine amplicons, analyzed in three multiplex PCRs. EMMA was performed as previously
described using EMMA polymer and according to the manufacturer’s instructions 37.
Amplicons showing abnormal profiles were sequenced and analyzed on the ABI PRISM
3130XL Genetic Analyser using the Collection and Sequence Analysis software package
(Applied Biosystems, Courtaboeuf, France). Nucleotide position was indicated on the basis
of the coding sequence NM_000314.4 and according to the recommended guidelines
(available at http://www.emqn.org/emqn.php and www.hgvs.org/mutnomen).
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Quantitative multiplex PCR (QMP) was carried out with 200 ng of tumor DNA sample,
measured on a NanoDrop (ND-1000, Labtech International, France). All primers were
designed in order to include flanking intronic sequences and prevent the detection of the
processed pseudogene (PTEN1) that presents 98.6% homology to the cDNA of PTEN (the
sequences of primers are available upon request). Amplicon sizes ranged from 111-347 bp.
Exons of the PTEN gene were analyzed by two assays consisting of four and five PTEN
amplicons, one amplicon of two genes proximal to PTEN (PAPSS2 and KILLIN) and
amplicons of the MSH2 and BRCA1 genes used as internal control for copy number
analysis. Multiplex PCRs were performed with the Qiagen Multiplex PCR kit, according to
the manufacturer’s recommendations (Qiagen, Courtaboeuf, France), and 1 μl of 10X
primer mix (final concentration from one to 10 μmol/L of each primer), one of them
carrying a 6-FAM label. Eight per cent DMSO was added for the assay including PTEN
exon 1 and KILLIN amplicons. Amplification was performed as recommended by the
manufacturer (Qiagen) and 24 cycles were performed for quantitative PCR. DNA fragments
generated by QMP were separated by capillary electrophoresis on the ABI 3130XL Genetic
Analyser (Applied Biosystems). Data were analyzed with the GeneMapper Software V4.0
and copy number variation was evaluated for each amplicon by calculating the relative peak
height for each sample with respect to the mean value of the relative peak height observed in
all samples.
Immunohistochemistry
Immunohistochemistry (IHC) for p53 (1:800, DO7, Dako, Carpinteria, CA), HDM2 (1:50,
clone# 1F2,Calbiochem), p14 (1:1000, clone 4C6/4, Cell Signaling, Danvers, MA), p-S6K
(1:50, clone Ser235/236, Cell Signaling), p-4eBP1 (1:500, clone Thr37/46, Cell Signaling),
and p44/p-ERK (1:50; clone Thr202/Tyr204, Cell Signaling) was performed according to
manufacturer’s recommendations. The immunoreactivity scoring was counted as the
percentage of nuclear staining per 10 high-power fields, in several areas, regardless of
staining intensity. A 20% cutoff value for detection of positive nuclear reactivities was
selected for all antibodies. 38, 39
Statistical analysis
Descriptive statistics were used to show the distribution of variables in the population.
Differences between groups were evaluated by χ2 test or Fisher’s exact test for categorical
variables and t test for continuous variables. The statistical analysis of baseline
demographics and clinical outcome is based on all data available up to the cut-off date, 31
August 2011. Disease-free survival was defined as the length of time after diagnosis during
which patients had no evidence of disease and was estimated with the use of the Kaplan–
Meier method.
RESULTS
TP53 gene alterations are very rare in angiosarcomas
TP53 deletions have been reported to be frequent events in sarcomas with complex
karyotypes, especially LMS and UPS. To assess the frequency of this aberration in AS, we
analyzed 18 tumors (6 primary and 12 secondary) by array CGH, none of which exhibited
copy number loss of the TP53 gene. We then analyzed the mutational status of TP53 by
sequencing exons 2-11 on genomic DNA in 52 tumors. We found a TP53 mutation in only
two cases (4%) (A138S exon 5, R238Q exon 7), which were not present in the
corresponding germline DNA from the same patient. Both cases with TP53 mutation
occurred in patients with a secondary breast AS developed in a previously irradiated field
(AS10, AS17). Both tumors carried MYC amplification and one of them a KDR A1065T
exon 24 mutation (AS17), as previously reported 40. Moreover, we observed a R72P
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polymorphism in TP53 exon 4 in 30 cases (58%), including 19 secondary and 11 primary
AS. P53 protein expression was then assessed by IHC in 46 cases. Twenty-three tumors
(50%) were negative for p53 expression and 23 (50%) were positive (including the two
tumors with TP53 mutation). There was no significant difference of p53 IHC status between
primary and secondary AS. Moreover, there was no correlation between the presence of the
R72P polymorphism and protein expression.
p53 protein expression correlates with disease-free survival in angiosarcoma
Since p53 protein status assessed by IHC was previously associated with outcome in several
tumor types, including sarcomas with complex genomics, we decided to analyze its
correlation with clinical behavior in AS. We found that p53 positivity (defined as >20%
nuclear positivity) was significantly associated with worse disease-free survival: 3.4 months
(95% CI: 0.8-6) versus 14.9 months (95% CI: 2.5-27.4), p= 0.002 (Figure 1).
p14 inactivation or HDM2 overexpression does not substitute for TP53 inactivation in
angiosarcoma
Since p14 is implicated in p53 degradation by proteasome through its interaction with
HDM2, we analyzed the p14 and MDM2 copy number alterations by array CGH and their
expression level (real-time PCR, IHC) in order to identify the potential loss of p14
expression or HDM2 overexpression, which could compensate for a lack of TP53
inactivation. However, no deletion of the CDKN2A locus encoding for P14 or MDM2
amplification was observed by array CGH. Real-time RT-PCR was performed for 19 tumors
(10 secondary AS and nine primary AS) and did not reveal any significant difference in P14
or MDM2 expression between primary and secondary AS or between AS and other vascular
tumors (data not shown). Immunohistochemistry was performed for 43 tumors. We observed
P14 and HDM2 expression in 36 tumors out of 40 (89%) and 6 tumors out of 40 (15%) with
interpretable results, respectively. We found a concordance between the presence/absence of
p14 overexpression and absence/presence of HDM2 expression in 81% of cases.
No PTEN intragenic mutations or deletions are detected in angiosarcoma
PTEN deletion is a frequent event in sarcomas with complex karyotypes. In order to assess
the incidence of this genomic aberration in AS, we analyzed a series of 26 tumors using
QMP to detect gross genomic rearrangements and by array CGH to detect smaller deletions.
Six cases revealed a duplication of all the exons of PTEN, whereas eight cases revealed
deletion of all the exons. No case with intragenic rearrangement or deletion was identified.
These results indicate the presence of large genomic imbalance involving chromosome 10
but do not favor PTEN as a target gene. We then used EMMA in order to detect point
mutations that may inactivate the function of PTEN and substitute the absence of specific
deletion. We did not find PTEN mutations in this series of AS. We analyzed the expression
of PTEN gene using published expression data from a series of 21 AS and 3 other vascular
tumors previously studied on the U133A Affymetrix platform40. Although the expression of
PTEN was relatively low, it was uniform across the samples and similar between AS and
other vascular tumors.
The PIK3CA/AKT/mTOR pathway is activated in a subset of angiosarcoma
Previous studies suggested a crucial role of the PIK3CA/AKT/mTOR pathway in the
malignant transformation of endothelial cells. Although, PTEN did not appear to be
specifically altered in AS we hypothesized that the PIK3CA/AKT/mTOR pathway was
activated through alternative mechanisms in at least a subset of AS. We therefore performed
further immunohistochemical analyses to evaluate the expression of p-S6K and p-4eBP1
(4E-binding protein 1), two downstream targets of mTORC1. We also evaluated the
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activation of the ERK pathway due to its multiple interactions with the PIK3CA/AKT/
mTOR pathway and its potential involvement in the phosphorylation of S6 ribosomal
protein. We found that 17 tumors out of 40 AS (42%) were positive for pS6K and/or
p-4eBP1. We observed also that 12 tumors of 39 (31%) were positive for p44/p-ERK.
Eleven of the 17 tumors positive for p-S6K and/or p-4eBP1 were also positive for p44/p-
ERK (Pearson correlation coefficient 0.6; P=0.02). Then we investigated the incidence of
point mutations in PIK3CA by screening this gene for 13 common hot spot mutations in
exons 3, 10 and 20 in 33 cases of AS (22 secondary and 11 primary). We found a recurrent
truncating frame shift mutation in exon 10 of the PI3KCA gene (S553fs) in 13 cases (39%)
including five primary and eight secondary AS. This mutation was then confirmed by PCR
using mutant-specific allele exon 10 primers (Fwd: 5′-
CAGTTACTATTCTGTGACTGGTGT-3′; Rev: 5′-AGATTTTCTATGGACCACAGG-3′,
Fig. S1). In order to explore further the biological significance of this unusual mutation, we
sequenced the cDNA of three mutated cases with available RNA. However, no mutation was
identified suggesting that the mutant PIK3CA transcript undergoes a nonsense-mediated
decay and therefore is not detectable at the cDNA level (Fig. S1). Moreover, there was no
correlation between the PI3KCA mutational status and the p-S6K and/or p-4eBP1
immunohistochemistry results.
NRAS and BRAF are not mutated in angiosarcomas
Given the high proportion of AS being positive for p44/ERK IHC in our series and the
potential role of RAS dysregulation in abnormal vascular growth control, we hypothesized
that a subset of AS are associated with mutation of the BRAF or NRAS genes. We screened
BRAF exon 15 and NRAS exons 2 and 3 in 52 cases of AS, however, no mutations were
identified at these hot spots.
DISCUSSION
Recent studies investigating the TP53 pathway in large series of sarcomas with complex
genomics (LMS, UPS and pleomorphic liposarcomas) have shown that TP53 alterations are
highly recurrent in this group of disease with up to 80% of cases exhibiting at least one
TP53 alteration (mutation and/or deletion) 21-23. Our results showing deletion and mutation
rates of 0% and 4%, respectively, indicate that AS display a different TP53 alteration profile
than the majority of other sarcomas with complex karyotypes. Our findings are in agreement
with previous smaller scale reports suggesting that TP53 mutations are uncommon in
AS 28, 30.
Interestingly, a P72R polymorphism in exon 4 was detected in 58% of the analyzed cases.
Unlike the deleterious tumor-associated P53 mutations, which occur in about 98% of cases
in the DNA-binding-domain of the protein, single nucleotide polymorphisms are expected to
be phenotypically silent. The R72P polymorphism occurs in the polyproline domain, which
lies between the N-terminal transactivating domain and the DNA-binding domain of p53.
This polymorphism has been associated with a modulation of the pro-apoptotic potential of
p53 and cancer susceptibility 41. However, the level of evidence is poor due to important
methodological issues and several meta-analyses failed to demonstrate a risk between the
R72P polymorphism and any cancer 41. Interestingly, a high incidence of this polymorphism
has been recently reported in atypical vascular lesions occurring after radiotherapy 35. In our
series, we have observed this SNP in both primary and secondary AS suggesting the absence
of any link between this polymorphism and the etiology of AS.
The rarity of deleterious TP53 mutations or deletions in AS does not necessarily imply that
the TP53 pathway is intact and functional in these tumors. p14 acts on the TP53 pathway by
interacting with HDM2, an E3 ubiquitin ligase targeting p53 for degradation by the
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proteasome. This results in a stabilization and activation of p53. Loss of p14 expression and/
or HDM2 overexpression are frequent in sarcomas and have been shown to substitute for
p53 inactivation in tumors without TP53 gene aberrations. Our results indicate that these
genetic aberrations are not commonly involved in AS genesis. Despite these results, we
observed a high proportion of AS displaying p53 overexpression. Normal p53 protein has an
extremely short half-life and it is not detected by IHC. However, following genotoxic stress,
the p53 protein level increases rapidly due to stabilization through post-transcriptional
mechanisms. In contrast, mutation of the TP53 gene results in nuclear accumulation of the
abnormal protein, which has a longer half-life and can be detected by IHC. Based on the
assumption that only stable (presumably mutated) protein will be expressed, TP53 IHC is
often used as a surrogate to predict the presence of TP53 mutations. In our study, however,
we observed a high level of discordance between the IHC and the sequencing results.
Although the two cases harboring a TP53 mutation were found to be positive upon
immunostaining, 21 cases harboring wild-type TP53 stained also positive. Such
discrepancies have already been reported in several studies suggesting that IHC is not a
reliable tool for TP53 mutation screening42, 43. One hypothesis is that this overexpression is
the result of specific oncogenic stresses leading to stabilization of the wild-type protein. In
this case, we would expect to observe an improved outcome as the result of increased tumor
apoptosis, which was not the case. A second hypothesis is that the nuclear accumulation of
p53 is dependent on mechanisms different from mutation and reflects functional changes.
Interestingly, p53 overexpression by IHC has been identified as a strong prognostic factor in
many human cancers, including soft-tissue sarcomas 42, 43. Our data indicate that this
biomarker has also a prognostic value in AS.
We have also shown that in contrast with other sarcomas with complex genomics, PTEN is
neither deleted nor mutated in AS. Moreover, our expression data showing similar level of
PTEN expression across the AS cases and other vascular tumors suggest that epigenetic
silencing or transcriptional defect of PTEN is unlikely. All together, our results are in
agreement with previous reports showing that constitutional biallelic inactivation of PTEN
was associated with vascular malformation, but not with malignant vascular tumors 44.
Despite the lack of PTEN alteration in AS, we have identified an activation of the PIK3CA/
AKT/mTOR pathway in a significant proportion of cases. Several studies have already
demonstrated the crucial role of PIK3CA/AKT/mTOR signaling in endothelial cell
homeostasis 45. Moreover, embryonal fibroblasts transformed with the PI3KCA gene have
been shown to induce AS at the site of injection in chicken 46, 47. Interestingly, we have
found a recurrent frameshift mutation affecting the helical domain of PI3KCA in about 40%
of cases. The same mutation has been recently reported at a low incidence rate in one case of
large B cell lymphoma 48 and one case of synovial sarcoma 49. Our results showing that this
mutation is not detectable at cDNA level strongly suggest that this aberration does not have
functional consequence. Therefore, further studies are needed to identify the mechanisms
involved in the activation of PIK3CA/AKT/mTOR activation in AS. Indeed, the patterns of
regulation of the PIK3CA/AKT/mTOR pathway in cancer cells are very complex and cross-
talk with several other pathways. For instance, it is now recognized that PI3KCA and
MAPK signals converge upstream and downstream of mTORC1 50. Interestingly, we found
a good correlation between the activation of these two pathways in our series with the
majority of tumors positive for p-S6K and/or p-4eBP1 being also positive for p44/p-ERK.
Overall, our findings may have therapeutic implications, specifically that PI3KCA and/or
mTOR antagonists represent a promising approach in the systemic treatment of AS, as
already suggested by a recent in vitro study and preliminary clinical data 51, 52. They suggest
also that, besides the inhibition of VEGFR receptors, the inhibition of MAPK signaling may
be a relevant approach in AS as suggested by preclinical data 53 and may also contribute to
the recently described clinical activity of multi-target tyrosine kinase inhibitors such as
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sorafenib in AS 54. Moreover, synergy is suggested with the combination of mTOR and
MAPK inhibitors 50.
In summary, we have shown here that AS represents a distinct subgroup among sarcomas
with complex karyotypes. Although TP53 mutation and PTEN deletion are frequent in LMS
and UPS, these aberrations are not involved in the pathogenesis of AS. However, AS are
characterized by a complex pattern of alterations of the TP53 and PIK3CA/AKT/mTOR
pathways that is not dependent on the MYC amplification status. These results underscore
the complex coordinated regulation of the survival and growth-control pathways in AS. Our
results represent an important basis for further investigations with the aim of determining
how the activities of these pathways are coordinated in AS and for the design of new
therapeutic strategies.
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Immunohistochemical (IHC) results for p53 (A,B,C), p14 (D), HDM2 (E) and prognostic
impact of p53 expression (F). (A,B) Diffuse and strong nuclear reactivity for p53 in a
secondary AS associated with a TP53 mutation and KDR mutation (A: AS17, 200x) and a
primary AS without TP53 mutation (B: AS59, 200x). (C) Absence of expression of p53 in a
case of secondary AS (AS19, 200x). (D) Diffuse nuclear reactivity for p14 in a secondary
AS (AS20, 200x). (E) Absence of expression of HDM2 in a case of secondary AS (AS39,
200x). (F) Kaplan Meier curve for disease-free survival according to p53 IHC status (blue
line: negative; green line: positive).
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Immunohistochemical (IHC) results for p-S6K (A), p-4eBP1 (B) and p44/p-ERK (C).
Diffuse and strong reactivity for pS6K (A, 200x), p-4eBP1 (B, 200x) and p44/p-ERK (C,
200x) in a primary angiosarcoma (AS9).
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